Prostacyclin: effects on cyclic AMP in bone cells.

  title={Prostacyclin: effects on cyclic AMP in bone cells.},
  author={J. C. Robin and M J Brown and N. Weinfeld and R. Dziak},
  journal={Research communications in chemical pathology and pharmacology},
  volume={35 1},
  • J. Robin, M. Brown, R. Dziak
  • Published 1 July 1982
  • Biology, Medicine
  • Research communications in chemical pathology and pharmacology

Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.

Prostacyclin Suppresses Twist Expression in the Presence of Indomethacin in Bone Marrow-Derived Mesenchymal Stromal Cells

  • O. KemperM. Herten M. Jäger
  • Medicine, Biology
    Medical science monitor : international medical journal of experimental and clinical research
  • 2014
Iloprost partially antagonized the suppressing effects of indomethacin on BMSC differentiation towards the osteoblast lineage and might be counterbalanced by iloprost in the treatment of avascular osteonecrosis or painful bone marrow edema.

Serotonin 2B Receptor (5-HT2B R) Signals through Prostacyclin and PPAR-ß/δ in Osteoblasts

It is concluded that the absence of 5-HT2B receptors leads to the overproduction of prostacyclin, inducing reduced osteoblast differentiation due to PPAR-ß/δ -dependent target regulation and defective cell-cell adhesion and matrix mineralization.

Prostaglandins as Mediators of Bone Cell Metabolism

Prostaglandins are unsaturated, hydroxylated, 20-carbon fatty acids consisting of a five- membered ring and two aliphatic side chains that appear to be ubiquitous throughout the body.

Bone loss and bone blood flow in paraplegic rats treated with calcitonin, diphosphonate, and indomethacin

APD shows an outstanding effect on the bone loss at the very place where it occurs preferentially in the paraplegics (the trabecular metaphysis), but this and other effects affect the controls as well.

The role of Iloprost on bone edema and osteonecrosis: Safety and clinical results

The literature suggests that Iloprost administration can be a viable option in the management of bone marrow oedema and early stages of osteonecrosis, and its effect on bone homeostasis needs further elucidation.